Pulse Biosciences Completes AF Pivotal Trial Enrollment 3 Months Early
PLSE has more than doubled off its 52-week low of $12.56.
Summary
Pulse Biosciences hit its enrollment target of 164 evaluable patients in the NANOPULSE-AF pivotal study, three months ahead of the original 9-month timeline. The trial spans 15 clinical sites and evaluates the nPulse Cardiac Catheter System for drug-resistant paroxysmal atrial fibrillation. This follows the July 8-K that reported enrollment had passed the halfway mark, and the September 8-K confirming completion of the separate PRECISE-BTN thyroid nodule study. Reaching full enrollment early signals strong investigator demand and operational execution, de-risking the timeline to pivotal data. Primary endpoints will be assessed at 6 and 12 months post-ablation, with data expected at a future medical conference.
At the time of this announcement, PLSE was trading at $49.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $12.56 to $58.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.